Browse

A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as “best-in-disease” and sent shares down more than 30%.

Celcuity said a combination regimen with its experimental drug gedatolisib doubled patients' likelihood of survival without disease progression or death in a late-stage breast cancer trial. Executi…

A bipartisan group of Michigan lawmakers released a new bill that could greatly stifle the booming cross-border deals spree between Chinese and American biotechs. Rep. John Moolenaar (R-MI) and Rep…